An official website of the United States government.

This is not the current EPA website. To navigate to the current EPA website, please go to This website is historical material reflecting the EPA website as it existed on January 19, 2021. This website is no longer updated and links to external websites and some internal pages may not work. More information »

Science Advisor Programs

Exploration of Perinatal Pharmacokinetic Issues

EPA tasked Versar, Inc., to convene a team of five expert scientists to assist the Agency in exploring how it might improve risk assessment and toxicity testing paradigms currently in use, and ways to improve the evaluation of pharmacokinetic data in immature animals at various stages of development. A task was defined whose purpose was to develop a White Paper that would review the current state of pharmacokinetic knowledge in the animal and human perinatal population, defined as the unborn, infants and young children. Each technical expert addressed one of five different issue areas or aspects of the scope of work. This report was developed with an eye toward:
  1. Identifying information that would inform the development of future test guidelines and/or guidance documents related to this topic
  2. Identifying information or approaches that would assist EPA in improving existing noncancer risk assessment methodologies
You may need a PDF reader to view some of the files on this page. See EPA’s About PDF page to learn more.